Evaluation of the effectiveness of aprepitant for prevention of nausea and vomiting in patients with breast cancer
Chemotherapy regimen AС (doxorubicin and cyclophosphamide) is the most often used in adjuvant chemotherapy of breast cancer. AC regimen is high emetogenic. Objective – to evaluate the effectiveness of the combination of aprepitant, ondansetron and dexamethasone for the prevention of nausea and vomit...
Main Authors: | I. A. Koroleva, M. V. Kopp, A. M. Koroleva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2018-11-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/2758 |
Similar Items
-
CHEMOTHERAPY REGIMEN AC (DOXORUBICIN AND CYCLOPHOSPHAMIDE) IN BREAST CANCER – PREVENTION OF NAUSEA AND VOMITING
by: I. A. Koroleva, et al.
Published: (2017-11-01) -
A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients
by: Winnie Yeo, et al.
Published: (2020-04-01) -
Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting
by: Chae Seong Lim, et al.
Published: (2013-03-01) -
Cost-Effectiveness of Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting: A Systematic Review of Published Articles
by: Tingting Qiu, et al.
Published: (2021-08-01) -
The efficacy of combination of ondansetron and aprepitant on preventing the radiotherapy-induced nausea and vomiting
by: Hamid Emami, et al.
Published: (2015-01-01)